Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
STAT4-AS1 (STAT4 antisense RNA 1) is a long noncoding RNA transcribed antisense to the STAT4 gene. It is downregulated in T cells from asthmatic individuals. STAT4-AS1 inhibits differentiation of TH17 helper T cells by binding to and sequestering the master transcription factor RORγt in the cytoplasm, preventing its interaction with the IL-17 gene promoter and blocking its nuclear translocation. This results in attenuated IL-17 expression and dampened TH17-mediated responses. STAT4-AS1 also provides feedback regulation on STAT4 gene expression. Its involvement in TH17 cell biology identifies it as a potential therapeutic target and biomarker for asthma and other immune-mediated conditions characterized by aberrant IL-17 and TH17 responses. Currently, STAT4-AS1 itself is not targeted by approved drugs, but its mechanistic insight suggests promise for clinical translation in the future.
Direct binding to RORγt protein, inhibiting its ability to promote IL-17A transcription; Feedback suppression/expression of the positive-sense STAT4 gene; Modulation of TH17 cell differentiation by interfering with RORγt nuclear translocation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on STAT4 antisense RNA 1 (STAT4-AS1).